Trials / Recruiting
RecruitingNCT06545877
REKOVELLE PEN for S.C. Injection General Drug Use Survey (Controlled Ovarian Stimulation in Assisted Reproductive Technologies)
REKOVELLE® PEN S.C. Injection 12μg/36μg/72μg for Controlled Ovarian Stimulation in Assisted Reproductive Technologies - General Drug Use-results Survey
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This survey targets controlled ovarian stimulation with this drug for the development of multiple oocytes in women undergoing assisted reproduction (ART) such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).
Conditions
Timeline
- Start date
- 2022-09-16
- Primary completion
- 2026-02-28
- Completion
- 2029-06-22
- First posted
- 2024-08-09
- Last updated
- 2025-08-20
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT06545877. Inclusion in this directory is not an endorsement.